Zilucoplan

Zilucoplan is a macrocyclic peptide inhibitor of complement component C5, designed to block the terminal complement pathway by preventing C5 cleavage into C5a and C5b. This mechanism prevents formation of the membrane attack complex (MAC) that mediates tissue damage in complement-driven diseases.

The compound received FDA approval for generalized myasthenia gravis (gMG), an autoimmune disorder where antibodies against acetylcholine receptors activate complement at the neuromuscular junction, damaging the postsynaptic membrane. By blocking C5, zilucoplan prevents this complement-mediated destruction while preserving upstream complement functions important for immune defense.

Zilucoplan's macrocyclic peptide design provides several advantages: high target affinity through pre-organized binding conformation, enhanced metabolic stability compared to linear peptides, and subcutaneous self-administration convenience compared to intravenous monoclonal antibody therapies targeting the same pathway.

The compound represents an important validation of macrocyclic peptides as a drug modality, demonstrating that this molecular class can achieve the potency and pharmacokinetics required for chronic disease treatment. Research continues to explore zilucoplan's potential in other complement-mediated conditions and to apply lessons from its development to other macrocyclic peptide drug candidates.